After 20 years, industry critics bury skeptics, despite empirical vacuum

Barton, D.; Stossel, Thomas P.; Stell, Lance K.

doi:10.1111/ijcp.12438

Cited by 25 publications

(24 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Main outcomes of VTE considered in daily practice are mortality for VTE, recurrences for VTE (i.e. pulmonary embolism, EP and deep vein thrombosis, DVT), bleedings, mortality for bleeding and overall mortality according to data provided from international guidelines, clinical registries, randomised clinical trials and validated clinical experiences (3,4).…”

Section: Editorialmentioning

confidence: 99%

See 1 more Smart Citation

Conflicts of interest: a matter of transparency

Citrome

2015

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

Section: Editorialmentioning

confidence: 99%

“…It was written in response to two papers published in the same issue of the International Journal of Clinical Practice (2,3). In this issue, Clark et al discuss the problem of COI in non-pharmacological research (4).…”

mentioning

confidence: 99%

Conflicts of interest: a matter of transparency

Citrome

2015

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…Opponents of 126 heightened regulation charge that proof is still lacking that financial ties sway physicians' prescribing and referral decisions in ways that actually harm patients therapeutically. For example, while financial ties have been correlated with 127 more expensive drug prescribing, this does not mean patients are receiving 128 clinically inappropriate treatments. Standards of care are rarely uniform; wide variations exist in the way clinicians practice medicine.…”

Section: A Correlation Vs Causation: the Actual Causal Impact Of Fimentioning

confidence: 99%

Financial Conflicts in the New Era of Sunshine

Saver¹

2018

IHLR

View full text Add to dashboard Cite

The health care system has entered a new era of sunshine about financial conflicts. Disclosure, an increasingly favored regulatory approach, significantly expanded with enactment of the Physician Payments Sunshine Act, the first comprehensive federal legislation mandating public reporting of payments between industry and medicine. But is it making any difference? And what is all the increased disclosure actually revealing? This article critically analyzes the mixed experience with the Sunshine Act, what has been learned from the information generated, and the ramifications for health law and policy. This article also considers how, even in the new era of sunshine, many still important unknowns remain that complicate and potentially undermine successful financial conflicts regulation.One clear lesson from the Sunshine Act is that inherent implementation challenges, such as data identification and translation, can seriously undermine transparency as a regulatory tool. There are considerable doubts whether the law will significantly impact decision-making of primary audiences such as patients and physicians. At the same time, the Sunshine Act has generated valuable information about the nature and scope of financial ties between industry and medicine, such as variations by clinical specialty, type of payment, and physician gender, all of which have important implications for health law and policy and can inform future regulation. Notwithstanding greater transparency, a great deal unfortunately still remains unknown. A critical need for more evidentiary support exists in several key areas, including the actual causal impact of financial conflicts, the optimal way to disclose conflicts, what patients really think about financial relationships with industry, and the role of institutional conflict of interest committees in monitoring financial ties.

show abstract

“…Not surprisingly, there is considerable debate surrounding COI policies in health and medicine. While some practitioners and ethicists believe they are inadequate to manage the spread of commercialized medicine (a concern that seems to be borne out by Monash IVF's approach to defining and managing conflict of interest), others consider them an unnecessary intrusion that obstructs medical research and practice [41,42]. These two positions are clearly underpinned by different views about clinical virtue, and its ability to withstand commercialisation.…”

Section: Conflict Of Interest Policies As a Means Of Negotiating A Comentioning

confidence: 99%